Aging is the single most important risk factor for Alzheimer's disease (AD), which represents the most common cause of dementia in the world. Our group has shown that a naturally occurring switch from the TrkA to the p75 neurotrophin receptor system is responsible for the activation of amyloid p-peptide (A[3) that characterizes aging. Such an event occurs downstream of the aging program mediated by the insulin-like growth factor 1 receptor (IGF1-R), and leads to activation of neutral sphingomyelinase (nSMase), the enzyme that generates the lipid second messenger ceramide. Ceramide, in turn, is responsible for the molecular stabilization of BACE1 and the increased production of Ap. The above events can be blocked by genetic and biochemical approaches that target IGF1-R, p75NTR, or nSMase. In the Preliminary Studies Section, we report that ceramide regulates a transient form of lysine acetylation of nascent BACE1 that affects the molecular stability of the p secretase. This process involves lysine acetylation in the lumen of the ER/ERGIC and is followed by deacetylation in the lumen of the Golgi apparatus, once the nascent protein is fully mature. Given the role that BACE1 plays in the molecular pathogenesis of AD, our results have profound implications for the neurobiology of the disease. The central hypothesis of this proposal is that ceramide is the last output of a signaling pathway that controls AD-neuropatholoqy during aging. Specifically, we propose that ceramide regulates AB generation by affecting the acetylation and molecular stability of BACE1, the rate-limiting enzyme for the biogenesis of Ap.
Specific Aim 1 will study the biochemical properties of the acetyl-CoA membrane transporter, which translocates acetylCoA from the cytosol to the lumen of the ER, where it serves as donor of acetyl groups for the molecular stabilization of BACE1.
Specific Aim 2 will study the function and biochemical properties of two newly-identified acetylCoA:lysine acetyltransferases that are required for the molecular stabilization of BACE1, downstream of ceramide. For the execution of the above two Specific Aims, we have described a combination of biochemical and genetic approaches. The biochemical approaches include enzymatic assays, in vitro reconstitution, affinity purification, subcellular fractionation studies, and depletion studies. The genetic approaches include stable transfection and """"""""gene-silencing"""""""" of the above targets. Finally, translational research is described as part of our proposal to translate our findings into novel therapeutic approaches to prevent late-onset AD.

Public Health Relevance

Aging is the single most important risk factor for Alzheimer's disease (AD). Because of the increase in life expectancy that we are experiencing, AD is predicted to affect 45 million individuals worldwide by the year 2050. We have identified a novel molecular pathway that links aging to AD neuropathology. The long-term objective of this proposal is to characterize this pathway and design new approaches for the prevention of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG033514-04
Application #
8377730
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
4
Fiscal Year
2012
Total Cost
$137,721
Indirect Cost
$44,034
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Clark, Lindsay R; Koscik, Rebecca L; Allison, Samantha L et al. (2018) Hypertension and obesity moderate the relationship between ?-amyloid and cognitive decline in midlife. Alzheimers Dement :
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Martin, Stephen A; Souder, Dylan C; Miller, Karl N et al. (2018) GSK3? Regulates Brain Energy Metabolism. Cell Rep 23:1922-1931.e4
Swanson, Ashley; Wolf, Tovah; Sitzmann, Alli et al. (2018) Neuroinflammation in Alzheimer's disease: Pleiotropic roles for cytokines and neuronal pentraxins. Behav Brain Res 347:49-56
Gilmore-Bykovskyi, Andrea (2018) Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia. J Am Geriatr Soc 66 Suppl 1:S13-S16
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Johnson, Sterling C; Koscik, Rebecca L; Jonaitis, Erin M et al. (2018) The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. Alzheimers Dement (Amst) 10:130-142
Dougherty, Ryan J; Lindheimer, Jacob B; Stegner, Aaron J et al. (2018) An Objective Method to Accurately Measure Cardiorespiratory Fitness in Older Adults Who Cannot Satisfy Widely Used Oxygen Consumption Criteria. J Alzheimers Dis 61:601-611
Dempsey, Robert J; Varghese, Tomy; Jackson, Daren C et al. (2018) Carotid atherosclerotic plaque instability and cognition determined by ultrasound-measured plaque strain in asymptomatic patients with significant stenosis. J Neurosurg 128:111-119

Showing the most recent 10 out of 374 publications